站在肿瘤免疫治疗的转折点上，NK细胞疗法展现出的不仅仅是技术突破，更是治疗范式的根本变革。从T细胞主导的精准打击，到NK细胞构建的多维防御，这种转变预示着个体化医疗向系统化治疗的进化。未来3-5年，随着基因编辑、微流控培养等技术的成熟，NK细胞疗法有望在实体瘤治疗领域实现50%的有效率突破。对于行业而言，建立跨学科研发平台、完善细胞制备质控体系、探索联合治疗新方案，将成为破局的关键三步棋。当免疫系 ...

A multinational research team of clinicians and scientists from South Korea and Singapore has published positive findings ...

CAR NK cells are following closely behind. Cytovia has designed CAR NK cells against three targets: EGFR, GPC3 and CD38. The EGFR candidate is a dual-targeted CAR designed to hit both wild-type ...

Natural killer (NK) cells are the human body’s first line of defense against cancer and infections but tend to get knocked down by treatment with anti-CD38 antibodies. This is because NK cells ...

The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.

Its Product Pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia ...